NetworkNewsBreaks – Novavax, Inc. (NASDAQ: NVAX) Enrolls First Participant in Phase 1/2 Trial of NanoFlu™ Vaccine
Novavax (NASDAQ: NVAX) said this morning that it has enrolled the first participant in its phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M™ adjuvant (NanoFlu™) in older adults. The primary objective of the trial is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFlu in comparison to a licensed influenza vaccine, Fluzone® High-Dose (Fluzone HD). Data from the trial is expected by the end of 2017. “Our goal is to deliver a differentiated flu vaccine to the greater than $3 billion global seasonal influenza commercial market and…







